ProQR Therapeutics NV PRQR shares are trading higher by more than 52% after the company reported results Wednesday from its trial of QR-421a in Usher Syndrome, though the stock did not surge initially.
ProQR is a biopharmaceutical company that develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
Cellect Biotechnology Ltd - ADR APOP shares are trading higher after the company and Quoin Pharmaceuticals announced a strategic merger.
Cellect is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
